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In 2015 President Obama launched the Personalized Medicine Initiative to "enable health care providers to tailor treatment and prevention strategies to people's unique characteristics." 1 Clinical pharmacologists, in collaboration with other health care providers, have been key drivers of personalized medicine, particularly in the field of oncology, as their unique expertise and tools position them to facilitate the identification of a dose that adequately balances benefit and risk for diverse populations. Furthermore, a thorough evaluation of the relationship of exposure, treatment outcomes, and various patient factors during development can facilitate the selection of an appropriate dose for an individual patient postapproval. Described herein are examples of how optimizing dose selection during clinical development can improve treatment outcomes for a relatively broad patient population and an outline of the opportunities to select an appropriate dose for an individual patient. The goal of this article is to provide a balanced perspective on the role of clinical pharmacology in the development of novel oncology drug products.
Clinical Pharmacology and Dose Selection in Early Drug Development
Traditional dose selection is based on an assessment of tolerability in the first-in-human (FIH) trial; however, several additional factors can be considered when evaluating a dose for further clinical development, including the nonclinical pharmacology data and the preliminary clinical pharmacokinetic (PK), safety, and activity data. These data can serve as the basis for the development of population models and dose-response and exposure-response (ER) analyses to support the dose evaluated in the registration trials. The models can be refined as additional data become available. For example, 2 doses were evaluated during the clinical development of sonidegib based on nonclinical data and clinical safety, activity, and pharmacodynamic data from the FIH trial. The ER relationships-in concert with an evaluation of drug exposure based on dose modifications-demonstrated similar efficacy with different safety profiles for the 2 doses and supported the approval of the lower dose. The ER relationships for both safety and efficacy have also provided supportive evidence of the recommended dosing regimen for many drugs, including idelalisib and dasatinib, as outlined in Table 1 . These examples demonstrate how evaluating additional factors facilitated the identification of an active dose with a manageable safety profile for further evaluation.
As an alternative to the traditional rule-based maximum tolerated dose paradigm, model-based approaches (eg, continual reassessment method or escalation with overdose control) have been incorporated into some FIH trials. These model-based approaches incorporate diverse data to identify potential doses for future clinical trials. Although model-based approaches and population analyses are only currently being used to identify a dose (or a range of doses) for a well-described patient population (as established by the eligibility criteria outlined in a clinical trial protocol), these methods are an integral step in the application of personalized medicine. The information garnered from these models can help identify a dose for an individual patient postapproval by helping to describe the effects of vari- Idelalisib ER analyses suggested that the proposed dose in the marketing application was reasonable. No ER relationships were observed for the primary end points and for selected safety end points; however, most patients administered the proposed dose achieved minimal concentrations greater than the target concentration identified from in vitro assays. A lower starting dose was not recommended because the ER relationship with tumor size in the dose-finding study suggests that the lower exposure is associated with less clinical activity. A higher starting dose was not recommended because idelalisib is associated with hepatotoxicity, and higher exposures were associated with a greater incidence of diarrhea.
Ponatinib
The dose-response relationships indicated that the proposed dose of 45 mg once daily was not supported by dose intensity-response relationship for efficacy and safety and suggested that a lower dose may offer a better benefit-risk profile. Following its initial approval, ponatinib was temporarily withdrawn from the market following reports of serious adverse cardiovascular reactions. Ponatinib was subsequently reintroduced with a narrowed indication; changes to boxed warning, dosage and administration, warnings and precautions, and adverse reactions; a Risk Evaluation and Mitigation Strategy and several postmarket requirements were issued to evaluate the safety profile of ponatinib, including characterization of the safety and efficacy over a dose range. No PK samples were collected in the trials that supported the initial marketing application.
Roceletinib
A dose that reasonably balanced safety and efficacy was not identified during clinical development. Two different doses were proposed during the review of the initial drug application. ER analyses showed similar systemic exposures of rociletinib across the dose range, a similar response rate with overlapping confidence intervals for efficacy, and no major differences in safety. Furthermore, ER analyses suggested that incidences of grade 3 to 4 hyperglycemia and QTc prolongation increase with increased exposure of 2 metabolites. Additionally, because the acetylation of these metabolites may be mediated by NAT2, patients who are classified as NAT2 slow acetylators based on NAT2 genotype have higher exposures and are at increased risk for QTc prolongation and hyperglycemia.
Sonidegib
Two doses were selected for additional clinical development based on the nonclinical data and clinical data from the FIH trial. The higher dose selected was the maximum tolerated dose identified in the FIH trial using a traditional definition, and the lower dose selected was the lowest dose administered in the FIH trial that demonstrated activity.
Vandetanib ER analyses showed that dose does not appear to influence survival, and the available data suggested that a lower dose may provide similar survival benefit; however, these analyses demonstrated that the risk of specific adverse reactions increased with increasing steady-state concentrations. Additional analyses showed that the risk of QT/QTc interval prolongation substantially increased with higher doses.
ER indicates exposure-response; FIH, first-in-human; NAT2, N-acetyltransferase 2.
ous patient factors (such as age, weight, race, and organ function) on exposure, biomarkers, safety, and efficacy and by supporting the prospective evaluation of a dose in the registration trial for the general population and for well-defined specific populations. The prospective evaluation of a dose for well-defined specific populations in ongoing clinical safety and efficacy trials could reduce the need to conduct dedicated trials postmarket, including trials designed to determine a dose for patients with organ impairment or coadministered an interacting drug. Despite the clear utility of model-based approaches and ER analyses to aide in dose selection, the use of these methods is still very limited. These analyses typically occur too late in clinical development to effectively identify a dose that balances both safety and efficacy before submission of the marketing application. Furthermore, the utility of these analyses Shord S101 may be limited by a low treatment response or adverse event rate, a single dose level or the lack of comparator based on several recent examples in which the initial drug application was supported by a relatively small open-label trial or expansion cohort. As an example, ER analyses included in the marketing application for cabozantinib in conjunction with drug exposure data suggested that a lower dose may be as effective with improved tolerability. A postmarket trial was required to explore an alternative dose. Postmarket trials for several other oncology drugs, including trastuzumab, ado-trastuzumab emantasine, and vandetanib, have also been requested to explore alternative doses based on the analyses included in the marketing application as discussed in Table 1 . These examples demonstrate that it is imperative that the dose selected for evaluation in the registration trial be based on all available data. More than 1 dose may be evaluated in clinical safety and activity trials when feasible. Dose selection based on multiple factors, as illustrated with the examples described above, appears more likely to identify a dose that balances benefit to risk and may decrease the need for further dose exploration postmarket. An early collaboration could help identify a dose that adequately balances benefit and risk before submission of the marketing application, with the goal of improving outcomes for patients taking the drug following approval and reducing the need for postmarket trials to investigate alternative doses, which are typically difficult to conduct.
The Use of Clinical Pharmacology Modeling Approaches in Clinical Dose Selection
These examples highlight the potential benefits of developing models early in clinical development to evaluate the pontential doses for later clinical development. The development of these models represents a novel approach to dose selection and requires a thorough examination of all available nonclinical and clinical data at each milestone (eg, at the end of phase 1 and the end of phase 2); traditionally, dose selection focused on a single variable-the safety profile, as stated earlier. The nonclinical data used to build the model can include the in vitro and in vivo ER relationship. Examples of studies that provide such data include (1) interaction with various kinases in biochemical kinase assays; (2) inhibition of biological or biochemical function in tumor cell lines; or (3) inhibition of tumor growth in animal models. The ER relationships for safety and efficacy for similar compounds can also be used to help develop these models. The FIH trial could ideally build on the ER relationships described in the nonclinical models and establish ER relationships across a broad dose range in humans. By leveraging clinical activity, tolerability, and biomarkers, these models can be used to identify doses that are reasonably likely to balance clinical activity and safety. The models can then be used to support the dose or doses selected for later clinical trials; the incorporation of at least 2 doses supported by these models should be considered in the registration trials. Leveraging all available data appears to facilitate the identification of a dose that balances benefit to risk, as exemplified by the dose selection of idelalisib (Table 1) .
Despite the potential benefits of developing these models early in development, the utility of these models may be negatively affected by several factors, including limited access to tumor tissues, limited availability of reliable biomarkers, limited understanding of the relationship between the drug and its target, and a lack of biomarkers. For example, some drugs may demonstrate clinical activity by inhibiting multiple targets (eg, regorafenib, sorafenib, sunitinib), making it difficult to select a single marker likely to predict clinical benefit. Additionally, serial biopsies are not feasible for many tumors (eg, solid tumors) to assess the effect of the drug on a selected target following administration of a new drug product. Furthermore, there are limited data to support the best means to inhibit a target, such as sustained vs intermittent inhibition, the best exposure metric (eg, bound vs free concentrations, minimum or maximum concentrations, or area under the curve) that correlates with inhibition, and the degree of inhibition required to provide sustained clinical activity with minimal toxicity. These limitations can make it difficult to identify a reasonable biomarker to assess early clinical activity. Other possible concerns with the development of models include limited data from small study populations (eg rare diseases) and arbitrary data-collection time points (eg, dose-limiting toxicities only identified within 3 to 4 weeks following the first dose despite continuous dosing). Additional research to identify surrogate markers and to explore relationships between target engagement and activity or safety may allow greater utility of the available data and the model development. Despite these known limitations, the development of models early in clinical development appears to facilitate the identification of a dose for further clinical development and understanding of the potential patient factors that influence tolerability and clinical activity. The observations garnered from these models can subsequently be used to modify the proposed patient population in the registration trial and allow prospective evaluation of alternative doses for various specific populations. A broader patient population will then subsequently be enrolled in the registration trial, which may encourage faster enrollment, shorter duration for clinical development, and fewer postmarket studies.
Use of Clinical Pharmacology Models to Identify Intrinsic Factors Affecting Variability in Drug Exposures
Population models can also be used to identify covariates that affect interindividual variability, including weight, organ function, comedications, and other clinical factors. Potential factors that could influence a dose could be identified early by evaluating nonclinical data (such as metabolism and elimination) and clinical data (such as interindividual variability, and PK, safety, and activity data) from the FIH trial. An exploration of the relationship between drug exposure and various demographic factors, safety, and activity may help identify populations that may require an alternative dose (such as genetic factors or organ function) and identify responder populations (such as prognostic or predictive factors for drug response or adverse reactions). As an example, patients with organ impairment have typically been excluded from clinical trials as a means to reduce "noise"; however, it would be reasonable to evaluate the safety and efficacy of a drug in the patient population most likely to be prescribed the drug after marketingincluding patients with organ impairment. As an example, patients with mild or moderate organ impairment could be enrolled in the registration trials of a biologic product because renal and hepatic elimination are not typically involved in their catabolism. Additionally, patients with mild or moderate organ impairment could be enrolled into a trial evaluating a new small-molecule drug if available data suggest that renal or hepatic impairment is unlikely to affect the drug's elimination. Expanding the eligibility to include patients with organ impairment allows the tolerability of a drug to be carefully assessed, as some patients with organ impairment may experience more adverse reactions compared to patients with normal organ function, despite having no clinically meaningful changes in exposure (eg, brentuximab vedotin, 2 daratumumab 3 ). The potential effect of other covariates, such as race, sex, and age, could be explored if the initial PK data suggest high interpatient variability or if a group of outliers is observed. For example, the effect of weight on PK, safety, and efficacy of a monoclonal antibody could be explored early in development to determine the feasibility of flat dosing, as observed with several recent approvals (eg, nivolumab, pembrolizumab). When we understand the effects of various covariates early in development, doses that will likely balance activity and tolerability for various population can be prospectively evaluated, which could support the selection of a dose postapproval for an individual patient based on his/her unique characteristics.
The development of these models requires adequate data to inform the model. This can only be achieved by ensuring that all clinical trials include adequate PK, biomarker, and pharmacogenomic sampling and analysis plans to support model-based dose-finding trials and population and ER analyses. The failure to include PK or pharmacogenomic data in clinical trials and to adequately assess the dose in early clinical development has impeded the development of some oncology drugs, including ponatinib 4 and rociletinib, 5 as described in Table 1 . These examples further support the need for greater understanding of the relationship among biomarkers, clinical outcomes, PK, and genomics during drug development.
Use of Clinical Pharmacology Models to Identify Extrinsic Factors Affecting Variability in Drug Exposures
Along with the inclusion of adequate sampling and analysis plans in clinical trials, there is an opportunity to evaluate effect of food on the systemic absorption in the FIH trial. Oral oncology drugs have been historically labeled to be taken in the fasted state, 6 with limited or late investigation of the effects of food on the oral bioavailability. For example, the FIH trial can include an expansion cohort designed to examine the effect of food. The results can subsequently support the instructions regarding food intake in relation to drug administration in later clinical trials and ultimately inform the labeling of the drug. Early understanding of the safety profile, PK, and interindividual variability can provide vital information to identify the most appropriate means to administer the drug with regard to food. Other variables, such as age, underlying comorbidities, common comedications, and adherence, may be considered as well when selecting whether to recommend the administration of a new drug product with or without food. Several recently approved drugs highlight how understanding the effect of food can affect dose selection and labeling recommendations. For example, alectinib is a poorly soluble drug with the potential for poor gastrointestinal tolerability. These physiochemical properties suggest that food would likely affect oral bioavailability. The early clinical trials explored the PK and safety of various doses when alectinib was taken with food and supported the instructions in the registration trials for alectinib to be taken with food. In stark contrast, the investigation of the effect of food on the oral bioavailability of ceritinib and sonidegib was conducted late in clinical development. The investigation showed that food substantially increased the oral bioavailability of these drugs. A postmarket trial is currently ongoing for ceritinib to identify a dose to be given with food that demonstrates similar exposure to the labeled dose given without food to improve gastrointestinal tolerability. 7 In comparison, the recommended dose for sonidegib is without food, as sonidegib exposures observed with food have been associated with an increased risk of serious musculoskeletal adverse events. 8 These selected examples highlight the importance of understanding the physicochemical properties, patient population, and the effect of food on oral bioavailability before starting the registration trial.
Similarly, exploring the likelihood of drug interactions with common comedications is critical for informing the eligibility criteria and determining the need for dose adjustments. Typically, in vitro studies evaluate the potential of the new drug to be metabolized by the major cytochrome P450 enzymes and of the new drug to modulate these enzymes; the potential for the new drug to interact with transporters and acidreducing agents could also be evaluated before the start of the FIH trial. An understanding of the potential for drug interactions early in development can ensure that the initial clinical trials avoid the coadministration of drugs that can increase or decrease drug exposure and influence the selection of a safe and tolerable dose for future clinical trials. Additionally, if the drug appears to be metabolized by polymorphic enzymes, baseline germline DNA could be collected to evaluate the effect of common polymorphisms on the PK, tolerability, and activity of the new drug. ER analyses can also help determine the potential influence of the polymorphism on the drug's safety and efficacy and help identify an appropriate dose for intermediate or poor metabolizers before starting the registration trials, negating the need to exclude these patients from these trials. For example, the polymorphic N-acetyltransferase 2 substantially influenced the formation of 2 metabolites from the parent drug rociletinib 4 and, subsequently, the incidence of 2 serious adverse reactions (ie, hyperglycemia and QT/QTc interval prolongation). An early evaluation of the effect of common polymorphisms may have provided valuable data to identify a dose for slow acetylators. Additionally, it may be helpful to evaluate the potential for a drug interaction in clinical trials before the registration trial if traditional static or mechanistic models suggest that a drug interaction is likely in humans. Physiologically based pharmacokinetic models can provide supportive data by exploring alternative study populations, dosing intervals, or dosing regimens or by describing the effects of a moderate modulator on drug exposure. For example, clinical trials were conducted before the marketing application for sonidegib and alectinib, and the final labeling recommendations were supported by the results of these studies and additional modeling and stimulations. A potential for interaction with acid-reducing agents can be identified if the drug is a weak base that demonstrates poor solubility at pH levels greater than 6 and has pH-dependent solubility. 9 An early understanding of such potential for interactions with acid-reducing agents can also be valuable to determine an appropriate management strategy for these agents. For example, several anticancer drugs, including erlotinib, dasatinib, nilotinib, and gefitinib, interact with acid-reducing agents and require dose modifications or alternative medications. These examples highlight the importance of understanding the metabolic pathways and potential for drug interactions early in development. An early understanding of the influence of coadministered drugs can allow a broader population to be enrolled in the registration trial and provide more data to support dose selection for an individual patient postapproval.
Conclusions
The above examples highlight the successes of employing the principles of clinical pharmacology early in development of a select number of oncology drugs approved by the US Food and Drug Administration in the past 2 decades. These examples demonstrate the ability of clinical pharmacology to improve clinical benefit-risk ratio and personalize the dose for the overall population and several specific populations. Additionally, these examples show that evaluating various responses, biomarkers, and exposure metrics available from nonclinical studies and clinical trials using a myriad of tools, such as modeling, simulations, and statistics, along with other disciplines can support dosing recommendations for both the general study population and several specific populations. These efforts can support the prospective evaluation of multiple doses before the marketing application and the enrollment of a broader population in the registration trial. Subsequently, the prospective evaluation of multiple doses in these specific populations may facilitate dose individualization for patients with similar demographics and clinical factors postapproval. The examples described above also highlight some potential limitations in our current abilities to develop models that adequately describe the ER relationships and that may impede the ability to identify doses for specific populations or individual patients. Future investigations could focus on identifying biomarkers or exposure metrics that can serve as reasonable predictors of clinical outcomes and identifying a dosing regimen that permits adequate inhibition of the desired target. Additionally, future investigations could consider adapting the current approaches to describe the ER relationships for efficacy and safety for broader populations, which include patients with different underlying characteristics, such as age, weight, race, metabolic rate, and organ function. In conclusion, clinical pharmacologists are uniquely equipped to support the Personalized Medicine Initiative by contributing a thorough understanding of the ER relationship for a drug and the effect of various cofactors on this relationship before submission of the marketing application.
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